studies

es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA), immune chekpoint inhibitors vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsIMpassion-031 (all population), 2020 0.69 [0.25; 1.89] 0.69[0.25; 1.89]IMpassion-031 (all population), 202010%333NAnot evaluable deaths (OS) (extension)detailed resultsGeparNuevo, 2019 0.24 [0.03; 2.28] 0.24[0.03; 2.28]GeparNuevo, 201910%174NAnot evaluable events or deaths (EFS)detailed resultsIMpassion-031 (all population), 2020 0.76 [0.40; 1.44] KEYNOTE-522, 2020 0.63 [0.43; 0.93] 0.66[0.48; 0.92]IMpassion-031 (all population), 2020, KEYNOTE-522, 202020%1,507lownot evaluable pCR detailed resultsGeparNuevo, 2019 1.45 [0.80; 2.63] IMpassion-031 (all population), 2020 1.95 [1.26; 3.01] IMpassion-031 (PDL1>1%), 2020 2.23 [1.16; 4.30] KEYNOTE-522, 2020 13.60 [6.77; 27.33] 2.98[1.24; 7.19]GeparNuevo, 2019, IMpassion-031 (all population), 2020, IMpassion-031 (PDL1>1%), 2020, KEYNOTE-522, 2020489%1,263lownot evaluable AE (any grade)detailed resultsIMpassion-031 (all population), 2020 0.49 [0.02; 14.69] KEYNOTE-522, 2020 0.25 [0.01; 4.74] 0.33[0.04; 3.09]IMpassion-031 (all population), 2020, KEYNOTE-522, 202020%1,501lownot evaluable AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.10 [0.71; 1.72] KEYNOTE-522, 2020 1.35 [1.01; 1.80] 1.27[0.99; 1.62]IMpassion-031 (all population), 2020, KEYNOTE-522, 202020%1,501lownot evaluable AE leading to death (grade 5)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] IMpassion-031 (all population), 2020 1.02 [0.06; 16.42] 0.97[0.10; 9.43]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505lownot evaluable AE leading to treatment discontinuation (any grade)detailed resultsIMpassion-031 (all population), 2020 1.18 [0.70; 2.01] 1.18[0.70; 2.01]IMpassion-031 (all population), 202010%331NAnot evaluable SAE (any grade)detailed resultsGeparNuevo, 2019 0.88 [0.47; 1.66] IMpassion-031 (all population), 2020 2.00 [1.20; 3.36] 1.36[0.61; 3.02]GeparNuevo, 2019, IMpassion-031 (all population), 2020274%505lownot evaluable STRAE (any grade)detailed resultsIMpassion-031 (all population), 2020 1.58 [0.91; 2.75] 1.58[0.91; 2.75]IMpassion-031 (all population), 202010%331NAnot evaluable TRAE (any grade)detailed resultsIMpassion-031 (all population), 2020 0.98 [0.14; 7.05] KEYNOTE-522, 2020 0.25 [0.03; 2.00] 0.51[0.12; 2.15]IMpassion-031 (all population), 2020, KEYNOTE-522, 202020%1,501lownot evaluable TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.15 [0.74; 1.77] KEYNOTE-522, 2020 1.26 [0.96; 1.66] 1.23[0.97; 1.55]IMpassion-031 (all population), 2020, KEYNOTE-522, 202020%1,501lownot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-522, 2020 1.50 [0.16; 14.43] 1.50[0.16; 14.43]KEYNOTE-522, 202010%1,170NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsKEYNOTE-522, 2020 2.16 [1.53; 3.05] 2.16[1.53; 3.05]KEYNOTE-522, 202010%1,170NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] KEYNOTE-522, 2020 10.08 [0.59; 173.00] 4.58[0.46; 45.81]IMpassion-031 (all population), 2020, KEYNOTE-522, 202020%1,501lownot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 0.87 [0.36; 2.09] 0.87[0.36; 2.09]KEYNOTE-522, 202010%1,170NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.27 [0.91; 1.77] 1.27[0.91; 1.77]KEYNOTE-522, 202010%1,170NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.40 [0.65; 3.02] 1.40[0.65; 3.02]KEYNOTE-522, 202010%1,170NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] KEYNOTE-522, 2020 3.51 [0.43; 28.62] 3.02[0.51; 18.04]IMpassion-031 (all population), 2020, KEYNOTE-522, 202020%1,501lownot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 0.50 [0.01; 25.13] 0.50[0.01; 25.13]KEYNOTE-522, 202010%1,170NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 3.51 [0.43; 28.62] 3.51[0.43; 28.62]KEYNOTE-522, 202010%1,170NAnot evaluable Diabetes TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] KEYNOTE-522, 2020 1.99 [0.09; 44.34] 1.54[0.14; 17.56]IMpassion-031 (all population), 2020, KEYNOTE-522, 202020%1,501lownot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.71 [0.63; 4.67] 1.71[0.63; 4.67]KEYNOTE-522, 202010%1,170NAnot evaluable Dysgeusia TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 0.50 [0.01; 25.13] 0.50[0.01; 25.13]KEYNOTE-522, 202010%1,170NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 2.29 [0.94; 5.58] 2.29[0.94; 5.58]KEYNOTE-522, 202010%1,170NAnot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.13 [0.82; 1.57] 1.13[0.82; 1.57]KEYNOTE-522, 202010%1,170NAnot evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.51 [0.02; 15.24] 0.51[0.02; 15.24]IMpassion-031 (all population), 202010%331NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] KEYNOTE-522, 2020 9.06 [0.52; 156.66] 4.26[0.42; 42.77]IMpassion-031 (all population), 2020, KEYNOTE-522, 202020%1,501lownot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] KEYNOTE-522, 2020 1.99 [0.09; 44.34] 1.54[0.14; 17.56]IMpassion-031 (all population), 2020, KEYNOTE-522, 202020%1,501lownot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 8.04 [0.46; 140.38] 8.04[0.46; 140.38]KEYNOTE-522, 202010%1,170NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] KEYNOTE-522, 2020 3.00 [0.15; 59.96] 2.01[0.19; 21.80]IMpassion-031 (all population), 2020, KEYNOTE-522, 202020%1,501lownot evaluable Increase AST TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 9.67 [1.29; 72.54] 9.67[1.29; 72.54]KEYNOTE-522, 202010%1,170NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 2.34 [1.13; 4.86] 2.34[1.13; 4.86]KEYNOTE-522, 202010%1,170NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.06; 16.42] KEYNOTE-522, 2020 2.53 [0.86; 7.45] 2.24[0.82; 6.15]IMpassion-031 (all population), 2020, KEYNOTE-522, 202020%1,501lownot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 0.76 [0.57; 1.03] 0.76[0.57; 1.03]KEYNOTE-522, 202010%1,170NAnot evaluable Myocarditis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.99 [0.09; 44.34] 1.99[0.09; 44.34]KEYNOTE-522, 202010%1,170NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] KEYNOTE-522, 2020 0.50 [0.01; 25.13] 1.11[0.09; 14.55]IMpassion-031 (all population), 2020, KEYNOTE-522, 202020%1,501lownot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 2.64 [1.01; 6.94] 2.64[1.01; 6.94]KEYNOTE-522, 202010%1,170NAnot evaluable Nephritis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 7.03 [0.40; 124.15] 7.03[0.40; 124.15]KEYNOTE-522, 202010%1,170NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.06 [0.82; 1.38] 1.06[0.82; 1.38]KEYNOTE-522, 202010%1,170NAnot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 4.00 [0.21; 75.85] 4.00[0.21; 75.85]KEYNOTE-522, 202010%1,170NAnot evaluable Peripheral neuropathy TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.88 [0.62; 5.72] 1.88[0.62; 5.72]KEYNOTE-522, 202010%1,170NAnot evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.20 [0.42; 3.43] 1.20[0.42; 3.43]KEYNOTE-522, 202010%1,170NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] KEYNOTE-522, 2020 1.50 [0.16; 14.43] 1.65[0.25; 10.86]IMpassion-031 (all population), 2020, KEYNOTE-522, 202020%1,501lownot evaluable Pyrexia TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 4.02 [0.50; 32.22] 4.02[0.50; 32.22]KEYNOTE-522, 202010%1,170NAnot evaluable Rash TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.32; 3.23] KEYNOTE-522, 2020 3.51 [0.43; 28.62] 1.37[0.49; 3.84]IMpassion-031 (all population), 2020, KEYNOTE-522, 202022%1,501lownot evaluable Sarcoidosis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 0.50 [0.01; 25.13] 0.50[0.01; 25.13]KEYNOTE-522, 202010%1,170NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] KEYNOTE-522, 2020 15.50 [2.11; 114.09] 6.86[0.60; 79.02]IMpassion-031 (all population), 2020, KEYNOTE-522, 2020232%1,501lownot evaluable Stomatitis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 11.10 [0.65; 189.37] 11.10[0.65; 189.37]KEYNOTE-522, 202010%1,170NAnot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.99 [0.09; 44.34] 1.99[0.09; 44.34]KEYNOTE-522, 202010%1,170NAnot evaluable Uveitis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 0.50 [0.01; 25.13] 0.50[0.01; 25.13]KEYNOTE-522, 202010%1,170NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.51 [0.59; 3.82] 1.51[0.59; 3.82]KEYNOTE-522, 202010%1,170NAnot evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed resultsGeparNuevo, 2019 1.79 [0.06; 54.10] 1.79[0.06; 54.10]GeparNuevo, 201910%174NAnot evaluable Abdominal pain AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] IMpassion-031 (all population), 2020 0.51 [0.02; 15.24] 0.65[0.05; 8.46]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505lownot evaluable Alopecia AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] IMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 0.95[0.06; 15.32]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505lownot evaluable Anaemia AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.12; 6.46] IMpassion-031 (all population), 2020 1.21 [0.54; 2.69] 1.15[0.55; 2.43]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505lownot evaluable Arthralgia AE (grade 3-4)detailed resultsGeparNuevo, 2019 1.80 [0.16; 20.23] IMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.54[0.20; 12.07]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505moderatenot evaluable Asthenia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.54 [0.25; 9.32] 1.54[0.25; 9.32]IMpassion-031 (all population), 202010%331NAnot evaluable Back pain AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.44 [0.01; 13.37] IMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 0.63[0.05; 8.30]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505moderatenot evaluable Blood creatinine increased AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.05 [0.00; 0.89] 0.05[0.00; 0.89]GeparNuevo, 201910%174NAnot evaluable Constipation AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.05; 14.46] IMpassion-031 (all population), 2020 0.51 [0.02; 15.24] 0.71[0.08; 6.14]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505moderatenot evaluable Cough AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] IMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 0.95[0.06; 15.32]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505lownot evaluable Decreased appetite AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsGeparNuevo, 2019 5.49 [0.27; 111.35] IMpassion-031 (all population), 2020 4.15 [0.46; 37.53] 4.58[0.77; 27.06]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505lownot evaluable Dry skin AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] IMpassion-031 (all population), 2020 2.04 [0.07; 61.32] 1.43[0.11; 18.75]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505lownot evaluable Dysgeusia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Dyspepsia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] IMpassion-031 (all population), 2020 1.02 [0.14; 7.32] 0.99[0.17; 5.78]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505lownot evaluable Epistaxis AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] IMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 0.95[0.06; 15.32]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505lownot evaluable Fatigue AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.47 [0.15; 1.45] IMpassion-031 (all population), 2020 1.23 [0.37; 4.11] 0.74[0.29; 1.92]GeparNuevo, 2019, IMpassion-031 (all population), 2020224%505moderatenot evaluable Febrile neutropenia AE (grade 3-4)detailed resultsGeparNuevo, 2019 1.82 [0.32; 10.20] IMpassion-031 (all population), 2020 1.25 [0.61; 2.57] 1.32[0.68; 2.57]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505lownot evaluable Headache AE (grade 3-4)detailed resultsGeparNuevo, 2019 1.79 [0.06; 54.10] IMpassion-031 (all population), 2020 0.51 [0.02; 15.24] 0.95[0.09; 10.58]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505lownot evaluable Hypertension AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.84 [0.35; 2.00] 0.84[0.35; 2.00]IMpassion-031 (all population), 202010%331NAnot evaluable Hyperthyroidism AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Hypophysitis AE (grade 3-4)detailed resultsGeparNuevo, 2019 1.79 [0.06; 54.10] 1.79[0.06; 54.10]GeparNuevo, 201910%174NAnot evaluable Hypothyroidism AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Increase AST AE (grade 3-4)detailed resultsGeparNuevo, 2019 5.49 [0.27; 111.35] IMpassion-031 (all population), 2020 2.44 [0.62; 9.59] 2.80[0.81; 9.75]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505lownot evaluable Increased ALT AE (grade 3-4)detailed resultsGeparNuevo, 2019 1.20 [0.26; 5.51] IMpassion-031 (all population), 2020 0.91 [0.36; 2.30] 0.98[0.44; 2.17]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505lownot evaluable Infusion-related reaction AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] IMpassion-031 (all population), 2020 1.02 [0.06; 16.42] 0.97[0.10; 9.43]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505lownot evaluable Injury, poisoning and procedure AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.05; 14.46] 0.89[0.05; 14.46]GeparNuevo, 201910%174NAnot evaluable Lacrimation increased AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Leucopenia AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.84 [0.45; 1.57] IMpassion-031 (all population), 2020 1.86 [0.76; 4.55] 1.17[0.54; 2.51]GeparNuevo, 2019, IMpassion-031 (all population), 2020251%505moderatenot evaluable Mucosal inflammation AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] 2.04[0.07; 61.32]IMpassion-031 (all population), 202010%331NAnot evaluable Myalgia AE (grade 3-4)detailed resultsGeparNuevo, 2019 1.82 [0.32; 10.20] IMpassion-031 (all population), 2020 2.04 [0.07; 61.32] 1.86[0.40; 8.67]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505moderatenot evaluable Nausea AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.06 [0.00; 1.05] IMpassion-031 (all population), 2020 0.28 [0.06; 1.38] 0.20[0.05; 0.79]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505lownot evaluable Neutropenia AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.83 [0.45; 1.52] IMpassion-031 (all population), 2020 1.10 [0.65; 1.84] 0.98[0.66; 1.45]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505lownot evaluable Oropharyngeal pain AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] 2.04[0.07; 61.32]IMpassion-031 (all population), 202010%331NAnot evaluable Paraesthesia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Peripheral neuropathy AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.88 [0.33; 2.33] IMpassion-031 (all population), 2020 0.40 [0.08; 2.09] 0.72[0.31; 1.66]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505moderatenot evaluable Peripheral oedema AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.51 [0.02; 15.24] 0.51[0.02; 15.24]IMpassion-031 (all population), 202010%331NAnot evaluable Peripheral sensory neuropathy AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.28 [0.34; 4.86] 1.28[0.34; 4.86]IMpassion-031 (all population), 202010%331NAnot evaluable Pneumonitis AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Pruritus AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.25 [0.03; 2.26] 0.25[0.03; 2.26]IMpassion-031 (all population), 202010%331NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 4.11 [0.18; 91.86] 4.11[0.18; 91.86]IMpassion-031 (all population), 202010%331NAnot evaluable Rash AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.05; 14.46] IMpassion-031 (all population), 2020 4.15 [0.46; 37.53] 2.30[0.41; 12.93]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505lownot evaluable Stomatitis AE (grade 3-4)detailed resultsGeparNuevo, 2019 3.62 [0.16; 81.50] IMpassion-031 (all population), 2020 6.20 [0.31; 124.85] 4.79[0.55; 41.56]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505lownot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.44 [0.04; 4.94] 0.44[0.04; 4.94]GeparNuevo, 201910%174NAnot evaluable Vomiting AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.05; 14.46] IMpassion-031 (all population), 2020 2.05 [0.18; 22.82] 1.43[0.23; 8.88]GeparNuevo, 2019, IMpassion-031 (all population), 202020%505lownot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-06-02 02:15 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 142,305,306 - treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons